| Citation: |
KOU Tianlei, HE Xuan, ZHU Jinlei, SUN Shulei, LIU Jiyao, ZHENG Shufang. Expression and significance of p53, P16, cyclin D1, E-cadherin in liposarcoma[J]. Journal of Clinical Medicine in Practice, 2022, 26(19): 22-27. DOI: 10.7619/jcmp.20221104
|
To investigate the expression of p53, P16, cyclin D1, E-cadherin(E-cad) in liposarcoma, and their correlations with clinicopathological characteristics and prognosis of liposarcoma.
The liposarcoma and parasarcoma tissues of 42 patients diagnosed with liposarcoma were collected. The tissues were stained with hematoxylin and eosin (HE), and the p53, p16, cyclinD1 and E-cad expressions in the liposarcoma and parasarcoma tissues were detected by immunohistochemistry. The relationship of the expression of p53, p16, cyclinD1, and E-cad with the clinicopathological characteristics and prognosis of liposarcoma were analyzed.
HE staining results in mucinous liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma showed significant differences. The expressions of p53, p16, cyclinD1 and E-cad were mainly located in the nucleus of sarcoma cells. The positive expression rates of p53, p16, cyclinD1 and E-cad in liposarcoma tissues were 45.24%, 59.52%, 52.38% and 47.62%, respectively, and were 83.33%, 28.57%, 23.81% and 69.05%, respectively in parasarcoma tissues. Compared with the parasarcoma tissues, the positive expression rates of p53 and E-cad in liposarcoma tissues were lower, and the positive expression rates of p16 and cyclinD1 were higher(P < 0.05). The expressions of p53, p16, cyclinD1 and E-cad showed significant differences in different tumor sites, TNM stages, pathological types, local recurrence or not and distant metastasis or not (P < 0.05). All the 42 patients were followed up, with the follow-up rate of 100.00% (42/42). A total of 25 cases (59.52%) survived and 17 cases (40.48%) died of recurrence or deterioration of liposarcoma. The number of deaths in patients with p53 and E-cad positive expression was lower than that of p53 and E-cad negative expression (P < 0.05). The number of deaths in patients with positive expressions of P16 and cyclinD was more than that in patients with P16 negative expression and cyclinD1 negative expression, respectively (P < 0.05).
The p53, p16, cyclinD1 protein and E-cad are all abnormally expressed in liposarcoma. The protein expressions of p53, E-cad, P16 and cyclinD1 are correlated with sarcoma site, TNM stage, pathological type, local recurrence and distant metastasis. Patients with negative expression of p53 and E-cad and those with positive expression of P16 and cyclinD1 have poor prognosis.
| [1] |
THWAY K. Well-differentiated liposarcoma and dedifferentiated liposarcoma: an updated review[J]. Semin Diagn Pathol, 2019, 36(2): 112-121. doi: 10.1053/j.semdp.2019.02.006
|
| [2] |
GAHVARI Z, PARKES A. Dedifferentiated liposarcoma: systemic therapy options[J]. Curr Treat Options Oncol, 2020, 21(2): 15. doi: 10.1007/s11864-020-0705-7
|
| [3] |
DUFFY M J, SYNNOTT N C, CROWN J. Mutant p53 as a target for cancer treatment[J]. Eur J Cancer, 2017, 83: 258-265. doi: 10.1016/j.ejca.2017.06.023
|
| [4] |
GUAN K, LI H, ZUO Z, et al. The molecular mechanisms of protective role of Se on the G0/G1 phase arrest caused by AFB1 in broiler's thymocytes[J]. Biol Trace Elem Res, 2019, 189(2): 556-566. doi: 10.1007/s12011-018-1491-y
|
| [5] |
LIANG H X, SUN L B, LIU N J. RETRACTED: Neferine inhibits proliferation, migration and invasion of U251 glioma cells by down-regulation of miR-10b[J]. Biomed Pharmacother, 2019, 109: 1032-1040. doi: 10.1016/j.biopha.2018.10.122
|
| [6] |
AVALLONE G, MUSCATELLO L V, LEONI A, et al. p53 expression in canine liposarcoma correlates with myxoid variant and higher proliferative activity[J]. Vet Pathol, 2020, 57(5): 620-622. doi: 10.1177/0300985820941501
|
| [7] |
ZUCO V, PASQUALI S, TORTORETO M, et al. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation[J]. J Exp Clin Cancer Res, 2021, 40(1): 83. doi: 10.1186/s13046-021-01886-x
|
| [8] |
GONG L H, LIU W F, DING Y, et al. Dedifferentiated liposarcoma of extremities: a clinicopathologic analysis[J]. Zhonghua Bing Li Xue Za Zhi, 2018, 47(7): 511-516.
|
| [9] |
孙萍萍, 马茹, 王玲玲, 等. 114例腹膜后脂肪肉瘤临床病理特征及预后因素分析[J]. 中国肿瘤临床, 2020, 47(24): 1248-1253. doi: 10.3969/j.issn.1000-8179.2020.24.116
|
| [10] |
XIONG D, WU Y B, JIN C, et al. Elevated FUS/TLS expression is negatively associated with E-cadherin expression and prognosis of patients with non-small cell lung cancer[J]. Oncol Lett, 2018, 16(2): 1791-1800.
|
| [11] |
刘族志, 王秋玲, 赵永兴. 口腔癌患者口腔组织中P16、Ki-67、CyclinD1的表达及其临床意义[J]. 现代医学, 2019, 47(1): 1-4. doi: 10.3969/j.issn.1005-8982.2019.01.001
|
| [12] |
李庆. 皮肤鳞状细胞癌中p16、CyclinD1、pRb蛋白表达与临床病理特征的关系[J]. 医学理论与实践, 2018, 31(2): 177-179. https://www.cnki.com.cn/Article/CJFDTOTAL-YXLL201802008.htm
|
| [13] |
宇洪浩, 原泉, 王欢, 等. 骨肉瘤中cyclinD1和p53蛋白的表达及其意义[J]. 中国实验诊断学, 2018, 22(9): 1549-1550. doi: 10.3969/j.issn.1007-4287.2018.09.019
|
| 1. |
张盼，王禺，李秀娥，王彩娥，刘媛. 纤维蛋白原、D-二聚体及血栓四项在中老年肾病综合征患者检测中的应用价值. 中国临床实用医学. 2024(05): 29-34 .
| |
| 2. |
顾志坚. 血清降钙素原在重症感染患者临床治疗中的应用效果探讨. 系统医学. 2021(14): 35-38 .
| |
| 3. |
乐大峰，杨君华，李声凤. 肾病综合征合并感染患者血清D-二聚体、IL-6、TNF-α水平变化及临床意义. 热带医学杂志. 2021(09): 1205-1208 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: